DUAVEE

Bazedoxifene/conjugated estrogens

Combination of
Bazedoxifene	Selective estrogen receptor modulator
Conjugated estrogens	Conjugated estrogens
Clinical data
Trade names	Duavee
Routes of administration	Oral
ATC code	G03CC07 (WHO)
Legal status
Legal status	US: ℞-only
Identifiers
ChemSpider	none

The drug combination bazedoxifene/conjugated estrogens (trade name Duavee in the US) is a medication approved by the Food and Drug Administration (FDA) for the treatment of menopause symptoms and postmenopausal osteoporosis. It is a fixed-dose combination drug containing the selective estrogen receptor modulator bazedoxifene and conjugated estrogens being marketed by the pharmaceutical company Pfizer.

Duavee was approved by the US FDA on October 3, 2013, for use as a once-daily tablet. Pfizer expects the drug to become available in the first quarter of 2014.

...
Wikipedia